Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SEATTLE CANCER CARE ALLIANCE SELECTED AS AUTHORIZED TREATMENT CENTER FOR YESCARTA™ - A NOVEL, NEW IMMUNOTHERAPY TREATMENTPRN
08/12/2017 5:49 PM
Seattle Cancer Care Alliance Selected as Authorized Treatment Center for Yescarta™ - A Novel, New Immunotherapy TreatmentSCCA is one of the first in the U.S. - and only facility in NW - to provide this therapy PR Newswire
SEATTLE, Dec. 8, 2017
SEATTLE, Dec. 8, 2017 /PRNewswire/ -- Seattle Cancer Care Alliance (https://www.seattlecca.org/?utm_source=Press_Release&utm_medium=Referral_Link&utm_content=SCCAhomepage_link&utm_campaign=Yescarta_FY18&utm_id=) (SCCA) has been selected as the only center in the Northwest (and one of the first centers in the U.S.) to currently offer axicabtagene ciloleucel (axi-cel, also known by the brand name Yescarta (https://www.seattlecca.org/treatments/immunotherapy/yescarta?utm_source=Press_Release&utm_medium=Referral_Link&utm_content=Yescarta_Announcement_PressRelease&utm_campaign=Yescarta_FY18&utm_id=)™), a new immunotherapy, developed by Kite (https://www.kitepharma.com/) (a Gilead company), to help treat adults living with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.
This new engineered CAR T-cell therapy harnesses the power of a patient's own immune system to target and attack cancer cells. Non-Hodgkin's Lymphoma (NHL) is a type of blood cancer that includes multiple subtypes, all of which originate in a patient's lymphatic system. The American Cancer Society estimates that 72,240 people will be diagnosed with aggressive NHL this year, and that 20,140 will die from it.
"We are honored to be selected as a certified treatment center for this promising immunotherapy," said Dr. Nancy Davidson, executive director and president of Seattle Cancer Care Alliance. "Our staff has worked incredibly hard to develop the skillset required to provide such treatments, and we have great hope for what this new treatment means for patients living with NHL."
"About 60 percent of all NHL cases are classified as aggressive, meaning they are fast growing and often difficult to treat," said Dr. Davidson. "Axi-cel will provide us with a whole new treatment for NHL that we believe holds tremendous promise." More information on the effectiveness of axi-cel is available in Kite's press release (https://www.seattlecca.org/treatments/immunotherapy/yescarta?utm_source=Press_Release&utm_medium=Referral_Link&utm_content=Yescarta_Announcement_PressRelease&utm_campaign=Yescarta_FY18&utm_id=).
SCCA is among the top ranked cancer treatment hospitals in the country (in the top five, according to U.S. News and World Report's (https://health.usnews.com/best-hospitals/rankings/cancer) most recent ranking), with a history steeped in scientific research protocols and above-average outcomes for cancer patients.
"The FDA's first approval of a CAR T-cell therapy was for pediatric patients and young adults with a different type of blood cancer and while it is a major advance it impacted a relatively small number of patients," Said Dr. David Maloney, medical director of the Bezos Family Immunotherapy Clinic at Seattle Cancer Care Alliance and medical director of cellular immunotherapy at Fred Hutchinson Cancer Research Center, SCCA's research partner. "The agency's approval of this new therapy will likely help save thousands of lives over the next few years."
SCCA's leadership in immunotherapy has helped to create new treatments for patients with leukemia, lymphoma and numerous other cancers. Patients at SCCA have had access to a broad range of investigational treatments in clinical trials at SCCA, and these trials have led to treatments that have since become more broadly available. "Access at SCCA to novel treatments like axi-cel CAR T-cell therapy represents a major step forward in the evolution of cancer care," said Dr. Maloney. "It also demonstrates SCCA's leadership in the fight against cancer, and we're proud to be able to offer this promising new cancer treatment to our patients today." For more information visit SCCA's FAQ (https://www.seattlecca.org/treatments/immunotherapy/yescarta-faqs?utm_source=Press_Release&utm_medium=Referral_Link&utm_content=Yescarta_FAQ_PressRelease&utm_campaign=Yescarta_FY18&utm_id=) on axi-cel.
About Us
Seattle Cancer Care Alliance brings together the leading research teams and cancer specialists from Fred Hutch, Seattle Children's, and UW Medicine. One extraordinary group whose sole purpose is the pursuit of better, longer, richer lives of our patients. Based in Seattle's South Lake Union region, SCCA has six clinical care sites, including a medical oncology clinic at EvergreenHealth in Kirkland, Washington; medical and radiation oncology at UW Medicine/Northwest Hospital & Medical Center in Seattle, Washington, as well as network affiliation with hospitals in five states. For more information about SCCA, visit http://www.seattlecca.org.
View original content with
multimedia:http://www.prnewswire.com/news-releases/seattle-cancer-care-alliance-selected-as-authorized-treatment-center-for-yescarta--a-novel-new-immunotherapy-treatment-300569037.html
SOURCE Seattle Cancer Care Alliance
Josh Chaitin at (206) 650-4201 or josh@prposestrategies.com
Photo:
https://mma.prnewswire.com/media/617180/sccaseattle_Logo.jpg
Website:
http://www.seattlecca.org
Copyright (c) 2017 PR Newswire Association,LLC. All Rights Reserved.
nPn1Clp1ya
© Thomson Reuters 2017. All rights reserved.
Then something else.....
I hope. Or BB or something else......
A Novel Therapeutic Strategy for Cancer Using Phosphatidylserine Targeting Stearylamine-Bearing Cationic Liposomes
Manjarika De3, Sneha Ghosh3, Triparna Sen3,4, Md. Shadab5, Indranil Banerjee6, Santanu Basu, Nahid Ali'Correspondence information about the author Nahid AliEmail the author Nahid Ali
3These authors contributed equally to this work.
4Present address: Thoracic/Head & Neck Medical Oncology, Clinical Research Building, T8.3986, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
5Present address: Department of Dermatology, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
6Present address: School of Medical Science & Technology, Indian Institute of Technology Kharagpur, Kharagpur 721302, India
Published Online: December 01, 2017 Novel Therapeutic Strategy for Cancer Using Phosphatidylserine Targeting Stearylamine-Bearing Cationic Liposomes
http://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S2162-2531(17)30283-4
Enhanced efficacy of curcumin with phosphatidylserine-decorated nanoparticles in the treatment of hepatic fibrosis
Published online: 07 Dec 2017
https://www.google.at/url?sa=t&source=web&rct=j&url=http://www.tandfonline.com/doi/pdf/10.1080/10717544.2017.1399301&ved=2ahUKEwjvsOeAtvjXAhXNmLQKHTn5DqIQFjAAegQIBxAB&usg=AOvVaw0fAP4b1_XQ4SqebTTyyh_e
MORE THAN 2,000 DRUGS NOW IN CANCER IMMUNOTHERAPY RACERTRS
07/12/2017 3:53 PM
By Ben Hirschler
LONDON, Dec 7 (Reuters) - The race to develop new immunotherapy treatments against cancer has sparked an unprecedented explosion in the oncology drug pipeline, with more than 2,000 immune system-boosting agents now in development.
The result is a scramble for patients to enrol in clinical trials, duplication of effort and the likely ultimate failure of many projects, according to experts.
Aiman Shalabi of the non-profit Cancer Research Institute said on Thursday that a global analysis, the first of its kind, had found 940 immunotherapy drugs in clinical stage development, with a further 1,064 at the preclinical stage.
This year alone, 469 new clinical studies were started, with a target enrolment of 52,539 patients, according to data presented by Shalabi at a European Society for Medical Oncology meeting in Geneva and published in the Annals of Oncology.
"The field is very promising and has the potential to deliver many breakthroughs to change the standard of care of many cancer types," Shalabi and colleagues wrote in the journal. "However, it is also very crowded, fragmented and uncoordinated with significant duplication."
Roche ROG.S Chief Executive Severin Schwan is convinced the mass rush into the hot new field of immunotherapy will lead to multiple disappointments.
As the world's biggest cancer drug company, the Swiss group expects to emerge among a handful of winners but Schwan also sees many failures and a wave of consolidation.
"I cannot imagine in my wildest dreams that all of these medicines will make it to the market and be competitive. There will be an enormous drop-out from all these clinical trials, which means a lot of people that invested into these trials will lose money," he said in a interview on Wednesday. (Full Story)
"I would expect to see a few winners and many losers."
Shalabi said there needed to be to rethink of cancer research and development, with a focus on more collaboration between both companies and academia.
ROCHE ROG.S CEO SEES CHANCE TO BE AT FOREFRONT OF LUNG CANCER IMMUNOTHERAPY06-Dec-2017 19:00
By Ben Hirschler
LONDON, Dec 6 (Reuters) - After lagging rivals in cancer immunotherapies, Swiss drugmaker Roche ROG.S hopes to leap-frog into the lead in the biggest market, tackling previously untreated lung cancer.
"We have a real chance to be at the forefront here," Chief Executive Severin Schwan said on Wednesday. "Our ambition is to become a clear leader in the field of cancer immunotherapies."
At the same time he warned many investors would lose money across the industry as a large proportion of the hundreds of cancer trials now underway failed, leaving just a few winners.
His optimism for Roche has been buoyed by study results showing its immune-boosting medicine Tecentriq given with chemotherapy and the older drug Avastin significantly cut the risk of lung cancer worsening. (Full Story)
Researchers will detail the scale of that benefit, versus chemotherapy and Avastin alone, in a keenly awaited presentation at a medical meeting in Geneva on Thursday.
"We have the potential to get into the lead in first-line lung cancer," Schwan said. "In all likelihood we have a medicine here that will potentially change the standard of care ... but we will also have to see how it compares with other therapies."
Overall survival (OS) data will also be crucial in determining the ultimate winner in lung cancer - by far the biggest oncology market - since one of the main benefits of using immunotherapy is its long-lasting effects.
Roche does not yet have that OS data but initial observations are "encouraging" and it expects results in the first half of 2018, well ahead of OS findings with a competing drug combination including chemotherapy from Merck & Co MRK.N.
Schwan needs Tecentriq to be a success to help replace revenue from older biological cancer drugs whose patents have expired or will shortly, exposing them to cheaper so-called biosimilar competition.
"On the pipeline side, we're even more de-risked than a year ago ... but there is no doubt that the impact from biosimilars will be significant," Schwan told Reuters.
"On balance, I'm now very confident that we should be able to compensate for this erosion."
The Sidney Kimmel Comprehensive Cancer Center Director's Visiting Professor Lecture Series "Immunologic Checkpoint Blockade: Exploring Combinations and Mechanisms" featuring Jedd David Wolchok, MD, Ph.D. from Memorial Sloan Kettering Cancer Center, New York, NY
Jeff David Wolchok, MD, Ph.D.
Associate Director, Ludwig Center for Cancer Immunotherapy Memorial Sloan Kettering Cancer Center
Albert H. Owens Jr. Auditorium
Sponsored by: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Tomorrow!
https://www.hopkinsmedicine.org/scical/
“Resolvin” Cancer Cell Debris: Clearing Every Litter Bit Improves Therapy
Kill Cancer Gently, Kill Cancer More Completely
DEC 04, 2017
As it turns out, the surface of these cells have a lipid called phosphatidylserine, which “generates a 'cytokine storm' of pro-inflammatory pro-tumorigenic cytokines." This inflammatory process can act like a breeze that reignites the few smoldering cancer cells that survived the initial treatment. And with time, another cancer wildfire begins anew.
https://www.labroots.com/trending/cancer/7488/kill-cancer-gently-kill-cancer-completely
Abstract and Programme Book
Kick-off meeting of the
Netherlands Society for Extracellular Vesicles
(NLSEV)
Friday Nov 17th 2017, Utrecht
http://www.nlsev.nl/downloads/NLSEV2017%20Abstract%20book.pdf
Immunovaccine Announces Positive Clinical Data from Its Collaborative Combination Immunotherapy Trial in Advanced Ovarian Cancer - GNW
IMMVF - they know Bavituximab
Moffitt Cancer Center Treats First U.S. Patient with Newly FDA-Approved CAR-T Therapy - PRN
04-Dec-2017 13:03
Moffitt Cancer Center Treats First U.S. Patient with Newly FDA-Approved CAR-T TherapyYescarta™ for Non-Hodgkin Lymphoma Launches Global Commercial Use for Breakthrough Immunotherapy Treatment PR Newswire
TAMPA, Fla., Dec. 4, 2017
TAMPA, Fla., Dec. 4, 2017 /PRNewswire-USNewswire/ -- Moffitt Cancer Center (http://www.moffitt.org/) announced that last week it treated the first patient commercially in the United States with the recently Food and Drug Administration-approved Yescarta (http://www.gilead.com/news/press-releases/2017/10/kites-yescarta-axica..., a Chimeric Antigen Receptor T cell, or CAR-T, therapy for patients with diffuse large B cell lymphoma, an aggressive form of non-Hodgkin lymphoma. As commercial use for Yescarta gets underway, Moffitt is actively enrolling eligible patients, with ten individuals awaiting treatment.
"We are proud to lead worldwide efforts in this next phase of CAR-T treatment for lymphoma patients and bring this critical innovation to as many patients as possible," said Frederick Locke (https://moffitt.org/providers/frederick-locke/), M.D., vice chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy (https://moffitt.org/for-healthcare-providers/clinical-programs-and-ser...) at Moffitt. "The clinical trials showed us the incredible results this treatment can have for patients; we expect many lives will be extended as commercial opportunity expands first from the United States, to other countries around the world."
Yescarta, the first CAR-T therapy approved by the FDA for adult lymphoma, is indicated for patients whose cancer has failed two lines of chemotherapy. CAR-T is a personalized therapy using a patient's own immune cells, or T cells, to fight cancer. For this treatment, a patient's T cells are removed and engineered with additional receptors to help identify, attack and ultimately destroy the cancer cells. The re-engineered T cells are then infused back into the patient's body in a single treatment, enabling the body's immune system to better combat the disease.
Moffitt co-led the ZUMA-1 national clinical trial, serving as the first cancer center to treat patients in the investigational setting, in addition to the first commercial infusion, which took place Nov. 27 at the hospital's main campus in Tampa. Of the Moffitt patients currently enrolled, one has received the CAR-T infusion, six have undergone the initial T cell removal process known as apheresis, and four are scheduled for T cell removal in the next few weeks.
Yescarta, which is manufactured by Kite, a Gilead Company, received FDA approval on Oct. 18. Moffitt will present additional findings from the ZUMA-1 clinical trial, as well as results from new CAR-T therapy trials, at the American Society of Hematology Annual Meeting (http://www.hematology.org/Annual-Meeting/) Dec. 9-12 in Atlanta.
For more information on the commercial enrollment process or to speak with Dr. Locke and the Moffitt Cellular Immunotherapy team, please contact Kim Polacek at 813-745-7408 or Kim.Polacek@Moffitt.org.
About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 49 National Cancer Institute-designated Comprehensive Cancer Centers (http://www.cancer.gov/research/nci-role/cancer-centers), a distinction that recognizes Moffitt's excellence in research, clinical trials, prevention and cancer control. Moffitt is listed as one of the top 10 cancer hospitals in the nation and has been listed in U.S. News & World Report (http://health.usnews.com/best-hospitals/rankings/cancer) as one of the "Best Hospitals" for cancer care since 1999. Moffitt devotes more than 2 million square feet to research and patient care. Moffitt's expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet(®) status, its highest distinction. With more than 5,600 team members, Moffitt has an economic impact in the state of $2.1 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org (http://www.moffitt.org/), and follow the momentum on Facebook (http://www.facebook.com/MoffittCancerCenter), Twitter (https://twitter.com/moffittnews) and YouTube (http://www.youtube.com/user/MoffittNews).
View original content with
multimedia:http://www.prnewswire.com/news-releases/moffitt-cancer-center-treats-f...
SOURCE Moffitt Cancer Center
A slow “catch and release” process prolongs immune attack on cancer cells
Pls delete if posted already.
The researchers found that fatty molecules called phosphatidylserine (PS) on the cancer cells’ surfaces latched onto certain cytokines, including IFN?. “You have to think of them as sticky tape, which is decorating all these tumors,” Altan-Bonnet says. Imaging data suggested that PS molecules bind to IFN?, transport the cytokine inside the cell and ferry it back to the surface later to be released again.
https://ccr.cancer.gov/news/article/catch-and-release-a-weak-point-on-cancer-cells
Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy
ABSTRACT
Both in vivo data in preclinical cancer models and in vitro data with T cells from patients with advanced cancer support a role for Tim-3 blockade in promoting effective anti-tumor immunity. Consequently, there is considerable interest in the clinical development of antibody-based therapeutics that target Tim-3 for cancer immunotherapy. A challenge to this clinical development is the fact that several ligands for Tim-3 have been identified: galectin-9, phosphatidylserine, HMGB1, and most recently, CEACAM1. These observations raise the important question of which of these multiple receptor:ligand relationships must be blocked by an anti-Tim-3 antibody in order to achieve therapeutic efficacy. Here, we have examined the properties of anti-murine and anti-human Tim-3 antibodies that have shown functional efficacy and find that all antibodies bind to Tim-3 in a manner that interferes with Tim-3 binding to both phosphatidylserine and CEACAM1. Our data have implications for the understanding of Tim-3 biology and for the screening of anti-Tim-3 antibody candidates that will have functional properties in vivo.
http://www.tandfonline.com/doi/full/10.1080/2162402X.2017.1385690
Small molecule inhibition of Axl targets tumor immune suppression and enhances chemotherapy in pancreatic cancer.
Ludwig KF1, Du W2, Sorrelle N3, Wnuk-Lipinska K4, Topalovski M2, Toombs JE5, Cruz VH2, Yabuuchi S6, Rajeshkumar NV7, Maitra A8, Lorens JB9, Brekken RA10.
Author information
Abstract
Activation of the receptor tyrosine kinase Axl is associated with poor outcomes in pancreatic cancer (PDA), where it coordinately mediates immune evasion and drug resistance. Here we demonstrate that the selective Axl kinase inhibitor BGB324 targets the tumor-immune interface to blunt the aggressive traits of PDA cells in vitro and enhance gemcitibine efficacy in vivo. Axl signaling stimulates the TBK1-NF?B pathway and innate immune suppression in the tumor microenvironment. In tumor cells, BGB324 treatment drove epithelial differentiation, expression of nucleoside transporters affecting gemcitabine response and an immune stimulatory microenvironment. Our results establish a preclinical mechanistic rationale for the clinical development of Axl inhibitors to improve the treatment of PDA patients.
https://www.ncbi.nlm.nih.gov/pubmed/29180468
http://cancerres.aacrjournals.org/content/early/2017/11/23/0008-5472.CAN-17-1973
Who is waiting at $5,78 ???
1)Why the need and how to approach the functional diversity of extracellular vesicles
Mercedes Tkach, Joanna Kowal, Clotilde Théry
Published 20 November 2017
This is the prime source:
Resolvins suppress tumor growth and enhance cancer therapy
http://jem.rupress.org/content/early/2017/11/29/jem.20170681
I fully agree!
Just Info.
JOHNS HOPKINS HEALTH SYSTEM - 2-DRUG COMBINATION MAY BOOST IMMUNOTHERAPY RESPONSES IN LUNG CANCER PATIENTS
PUBT
11/30/2017 6:48 PM
Combination therapy attracts immune cells to fight tumors and blocks cancer gene MYC Johns Hopkins Kimmel Cancer Center researchers and colleagues have identified a novel drug combination therapy that could prime nonsmall cell lung cancers to respond better to immunotherapy. These so-called epigenetic therapy drugs, used together, achieved robust anti-tumor responses in human cancer cell lines and mice.
Credit: Michael Topper and Michelle Vaz
Johns Hopkins Kimmel Cancer Center researchers and colleagues have identified a novel drug combination therapy that could prime nonsmall cell lung cancers to respond better to immunotherapy. These so-called epigenetic therapy drugs, used together, achieved robust anti-tumor responses in human cancer cell lines and mice.
During the study, published Nov. 30, 2017, in the journal Cell, a team of researchers led by graduate student Michael Topper; research associate Michelle Vaz, Ph.D.; and senior author Stephen B. Baylin, M.D., (https://www.hopkinsmedicine.org/profiles/results/directory/profile/0800001/stephen-baylin) combined a demethylating drug called 5-azacytidine that chemically reignites some cancer suppressor genes' ability to operate, with one of three histone deacetylase inhibitor drugs (HDACis). The HDACis work against proteins called histone deacetylases that are involved in processes, such as cell copying and division, and can contribute to cancer development. The combination therapy triggered a chemical cascade that increased the attraction of immune cells to fight tumors and diminished the work of the cancer gene MYC. Based on these findings, investigators have launched a clinical trial of the combination therapy in patients with advanced, nonsmall cell lung cancer.
The development of therapeutic approaches for patients with lung cancer has been a critical medical need, says Baylin, the Virginia and Daniel K. Ludwig Professor of Cancer Research at the Kimmel Cancer Center. While immune checkpoint therapy has been 'a tremendous step forward, less than half of patients with lung cancer have benefited to date,' he says.
'In our study, the two-drug epigenetic therapy combination worked exceedingly well, even before putting in the immune checkpoint inhibitors,' Baylin says. 'In animal models of lung cancer, the two agents either prevented cancer from emerging or blunted the effects of more aggressive cancers. In both scenarios, a large component of the results involved an increase in immune recognition of the tumors.'
In a series of experiments, researchers studied the combination of 5-azacytidine with the HDACis entinostat, mocetinostat or givinostat in human cancer cell lines and in mouse models of nonsmall cell lung cancers. The treatments were found to alter the tumor microenvironment. In cancer cell lines, 5-azacytidine worked against the cancer gene MYC, causing down regulation of the entire MYC signaling program. Adding the HDACis further depleted MYC, and together the drugs subsequently caused actions that prevented cancer cell proliferation, simultaneously attracted more immune system T cells to the area of the tumor and activated these cells for tumor recognition.
In mouse models, the strongest response was observed when using 5-azacytidine plus givinostat. In one mouse model with a mutant form of nonsmall cell lung cancer, this drug combination given for three months yielded prevention of benign, precursor tumors from becoming cancers and caused 60 percent reduction of overall area of benign tumor appearance in the lungs. By contrast, a group of mice with the same form of lung cancer that were given a mock treatment universally developed large, cancerous lesions in the lungs.
In a second model of mice with established, aggressive, nonsmall cell lung cancer, treatment with an alternating schedule of 5-azacytidine with givinostat and of 5-azacytidine with mocetinostat not only reduced the growth of established, rapidly growing primary tumors but also dramatically reduced metastatic occurrence.
Baylin and colleagues at Memorial Sloan Kettering Cancer Center in New York and Fox Chase Cancer Center in Philadelphia have started a phase I/Ib clinical trial to evaluate if giving mocetinostat with a 5-azacytidinelike drug called guadecitabine can boost immune checkpoint therapy responses in patients with advanced, nonsmall cell lung cancers. The trial is part of the Van Andel Research Institute-Stand Up To Cancer Epigenetics Dream Team and is funded by Merck through the Stand Up To Cancer (SU2C) Catalyst program, an initiative led by SU2C to bring innovative cancer treatments to patients quickly. Matthew Hellmann, M.D., an author on the paper, will lead this trial at Memorial Sloan Kettering, and Jarushka Naidoo, M.B.B.Ch. (https://www.hopkinsmedicine.org/profiles/results/directory/profile/10002047/jarushka-naidoo), assistant professor of oncology, will lead at Johns Hopkins. For more information, click here (https://clinicaltrials.gov/show/NCT03220477).
In addition to Topper, Vaz and Baylin, other scientists contributing to the Cell paper include Michael J. Christina DeStefano Shields, Noushin Niknafs, Ray-Whay Chiu Yen, Alyssa Wenzel, Jessica Hicks, Matthew Ballew, Meredith Stone, Phuoc T. Tran, Cynthia A. Zahnow, Valsamo Anagnostou and Victor E. Velculescu of Johns Hopkins; Katherine B. Chiappinelli of the George Washington University Cancer Center; Matthew D. Hellmann of Memorial Sloan Kettering Cancer Center; and Pamela L. Strissel and Reiner Strick of the University-Clinic Erlangen in Germany.
The work was supported by grants from the Hodson Trust, the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, Stand Up To Cancer's Jim Toth Sr. Breakthrough Lung Cancer Research Award, the Commonwealth Foundation for Cancer Research and the Samuel Waxman Cancer Research Foundation Collaboration for a Cure. It also was supported by National Institutes of Health grants (CA12113, CA006973, CA180950) and the Van Andel Research Institute-Stand Up To Cancer Epigenetics Dream Team.
Johns Hopkins Health System published this content on 30 November 2017 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 30 November 2017 17:47:55 UTC.
Original document
https://www.hopkinsmedicine.org/news/media/releases/2_drug_combination_may_boost_immunotherapy_responses_in_lung_cancer_patients
Public permalink
http://www.publicnow.com/view/F9BA9954ED3BDF42965E9BC055385A854430D92E
(C) Copyright 2017 - Johns Hopkins Health System
nNDL68wBwM
Requirement of Gamma-Carboxyglutamic Acid Modification and Phosphatidylserine Binding for the Activation of Tyro3, Axl, and Mertk Receptors by Growth Arrest-Specific 6
https://www.frontiersin.org/articles/10.3389/fimmu.2017.01521/full
Study reveals cancer therapy's double-edged sword ... and how to blunt it
30-Nov-2017
Avid Bioservices Announces Appointment of Tracy Kinjerski as Vice President of Business Operations - GNW
29-Nov-2017 14:05
TUSTIN, Calif., Nov. 29, 2017 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), today announced the appointment of Tracy L. Kinjerski as vice president of business operations. Ms. Kinjerski is a senior business development executive with more than 17 years of experience in the biopharmaceutical industry, almost all of which have been focused in contract development and manufacturing. In her new role, she will be charged with driving growth in Avid’s contract development and manufacturing organization (CDMO) business through the strategic expansion and diversification of the company’s commercial and clinical client base. Her responsibilities will span business development, project management and marketing.
Ms. Kinjerski most recently served as senior director of global business development at CMC Biologics, a global CDMO. In that role, her efforts spearheading business development and client relationship management generated significant new business growth in less than one year of joining the company. Prior to CMC Biologics, Ms. Kinjerski spent nearly five years with Fujifilm Diosynth Biotechnologies, the global CDMO division for Fujifilm. During her tenure, she served as director of commercial development focused on the East Coast of the US, helping to grow the company’s clinical and commercial business through new client engagements spanning global pharmaceutical companies, biotechnology companies of all sizes and government projects. Ms. Kinjerski, who holds a master’s degree in biomedical sciences, has also served in business and commercial development leadership positions at Althea Technologies and Avecia Biologics Billingham (since acquired by Fujifilm Diosynth), two fully-integrated CDMOs serving the pharmaceutical and biotechnology industries.
“We feel fortunate to add an individual with the talent and experience of Tracy to our expanding team of CDMO industry veterans,” said Roger Lias, Ph.D., president of Avid Bioservices. “At Avid, we are acutely focused on positioning the company as a leading pure play CDMO and growing revenues, while at the same time strategically diversifying our client base and service offering. We believe that Tracy, with her proven track record of success in CDMO business development and client relations will play a key role in helping the company achieve these goals.”
Avid Bioservices was established as Peregrine’s internal biologics manufacturing and development group, and began formal operations in January 2002. The company has grown from an internal support operation to a full service CDMO serving leading biopharma companies. Avid was recently recognized as a leading CDMO by Life Science Leader as a recipient of multiple 2017 Contract Manufacturing Leadership Awards for Quality, Reliability, Capabilities, Expertise and Compatibility. The company has an outstanding regulatory inspection history, including 12 years of commercial manufacturing and state-of-the-art cGMP manufacturing facilities.
About Avid Bioservices, Inc.
Avid Bioservices, a wholly owned subsidiary of Peregrine Pharmaceuticals, provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With over 20 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, including 12 years of commercial manufacturing for products sold in 18 countries, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, lot release and stability testing, regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development, qualification/validation, process and product characterization. For more information about Avid, please visit www.avidbio.com.
About Peregrine Pharmaceuticals, Inc. Peregrine Pharmaceuticals, Inc. is a company transitioning from an R&D focused business to a pure play contract development and manufacturing organization (CDMO). Peregrine's in-house CDMO services, including cGMP manufacturing and development capabilities, are provided through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com).
The company is pursuing to license or sell its proprietary R&D assets, including its lead immunotherapy candidate, bavituximab, which is currently being evaluated in clinical trials in combination with immune stimulating therapies for the treatment of various cancers. For more information, please visit www.peregrineinc.com.
Contacts:
Kelly Pisarev Lord
Avid Bioservices, Inc.
(800) 987-8256
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
PPHM Reloaded LOL
Do we still burn the whit card?
28-Nov-2017 14:05 - PEREGRINE PHARMACEUTICALS, RONIN TRADING AND SW INVESTMENT MANAGEMENT ANNOUNCE SETTLEMENT AGREEMENT
28-Nov-2017 14:06 - PEREGRINE PHARMACEUTICALS - CO, ?RONIN TRADING, SW INVESTMENT MANAGEMENT ENTERED SETTLEMENT REGARDING COMPOSITION OF PEREGRINE'S BOARD, AMONG OTHERS
28-Nov-2017 14:09 - PEREGRINE PHARMACEUTICALS - ON NOV 27, DIRECTORS STEVEN KING,CARLTON JOHNSON,ERIC SWARTZ & DAVID POHL TENDERED RESIGNATION IMMEDIATELY FROM BOARD?
28-Nov-2017 14:09 - PEREGRINE PHARMACEUTICALS - ?VACANCIES CREATED BY THE DIRECTOR RESIGNATIONS IMMEDIATELY FILLED BY THREE INDIVIDUALS NOMINATED BY RONIN/SWIM
28-Nov-2017 14:10 - PEREGRINE PHARMACEUTICALS - RONIN/SWIM, WHICH COLLECTIVELY BENEFICIALLY OWNS 9.6 PCT OF CO, WITHDREW NOMINATION OF 6 CANDIDATES TO PEREGRINE'S BOARD?
28-Nov-2017 14:10 - PEREGRINE PHARMACEUTICALS - ?RONIN/SWIM ALSO AGREED TO SOME STANDSTILL RESTRICTIONS UNTIL DATE THAT IS 30 CALENDAR DAYS AFTER 2018 ANNUAL MEETING
28-Nov-2017 14:11 - PEREGRINE PHARMACEUTICALS INC - ?PEREGRINE HAS ALSO AGREED TO RE-NOMINATE A NUMBER OF RONIN/SWIM'S APPOINTEES AT 2018 ANNUAL MEETING OF STOCKHOLDERS?
BRIEF-Peregrine Pharma, Ronin Trading And SW Investment Management Announce Settlement Agreement - RTRS
28-Nov-2017 14:22
Nov 28 (Reuters) - Peregrine Pharmaceuticals Inc PPHM.O:
PEREGRINE PHARMACEUTICALS, RONIN TRADING AND SW INVESTMENT MANAGEMENT ANNOUNCE SETTLEMENT AGREEMENT
PEREGRINE PHARMACEUTICALS - CO, ?RONIN TRADING, SW INVESTMENT
MANAGEMENT ENTERED SETTLEMENT REGARDING COMPOSITION OF PEREGRINE'S BOARD, AMONG OTHERS
PEREGRINE PHARMACEUTICALS - ON NOV 27, DIRECTORS STEVEN KING,CARLTON JOHNSON,ERIC SWARTZ & DAVID POHL TENDERED RESIGNATION IMMEDIATELY FROM BOARD?
PEREGRINE PHARMACEUTICALS - ?VACANCIES CREATED BY THE DIRECTOR
RESIGNATIONS IMMEDIATELY FILLED BY THREE INDIVIDUALS NOMINATED BY RONIN/SWIM
PEREGRINE PHARMACEUTICALS - RONIN/SWIM, WHICH COLLECTIVELY BENEFICIALLY OWNS 9.6 PERCENT OF CO, WITHDREW NOMINATION OF 6 CANDIDATES TO PEREGRINE'S BOARD?
PEREGRINE PHARMACEUTICALS - ?RONIN/SWIM ALSO AGREED TO SOME
STANDSTILL RESTRICTIONS UNTIL DATE THAT IS 30 CALENDAR DAYS AFTER 2018 ANNUAL MEETING
PEREGRINE PHARMACEUTICALS INC - ?PEREGRINE HAS ALSO AGREED TO
RE-NOMINATE A NUMBER OF RONIN/SWIM'S APPOINTEES AT 2018 ANNUAL MEETING OF STOCKHOLDERS?
Phosphatidylserine targeted single-walled carbon nanotubes for photothermal ablation of bladder cancer
http://iopscience.iop.org/article/10.1088/1361-6528/aa9c0c
Context-dependent compensation among phosphatidylserine-recognition receptors
Kristen K. Penberthy, Claudia Rival, Laura S. Shankman, Michael H. Raymond, Jianye Zhang, Justin S. A. Perry, Chang Sup Lee, Claudia Z. Han, Suna Onengut-Gumuscu, Krzysztof Palczewski, et al.
(2017) SCIENTIFIC REPORTS
Thursday October 19th 2017
Session V: INFLAMMATORY PATHWAYS – Chair: Karsten Sauer (Pfizer)
9:00am - 9:20am: Jennifer Oyler-Yaniv (UCLA) – abstract #11
Catch and Release of Cytokines Mediated by Tumor Phosphatidylserine Converts Transient Exposure into Long-Lived Inflammation
https://www.lajollaic.org/wp-content/uploads/2017/05/FINAL-LJIC-2017-program-abstracts.pdf?bcsi_scan_1014b4c4c7c5e188=0&bcsi_scan_filename=FINAL-LJIC-2017-program-abstracts.pdf
CAR-T cell therapy in ovarian cancer: from the bench to the bedside
Great post - must read! IMO
Prospects for combined use of oncolytic viruses and CAR T-cells.
Abstract
With the approval of talimogene laherparepvec (T-VEC) for inoperable locally advanced or metastatic malignant melanoma in the USA and Europe, oncolytic virotherapy is now emerging as a viable therapeutic option for cancer patients. In parallel, following the favourable results of several clinical trials, adoptive cell transfer using chimeric antigen receptor (CAR)-redirected T-cells is anticipated to enter routine clinical practice for the management of chemotherapy-refractory B-cell malignancies. However, CAR T-cell therapy for patients with advanced solid tumours has proved far less successful. This Review draws upon recent advances in the design of novel oncolytic viruses and CAR T-cells and provides a comprehensive overview of the synergistic potential of combination oncolytic virotherapy with CAR T-cell adoptive cell transfer for the management of solid tumours, drawing particular attention to the methods by which recombinant oncolytic viruses may augment CAR T-cell trafficking into the tumour microenvironment, mitigate or reverse local immunosuppression and enhance CAR T-cell effector function and persistence.
https://www.ncbi.nlm.nih.gov/pubmed/29157300
Phosphatidylserine targeted single-walled carbon nanotubes for photothermal ablation of bladder cancer.
https://www.ncbi.nlm.nih.gov/pubmed/29160225
Myeloid-Derived Suppressor Cells
Dmitry I. Gabrilovich
Published January 2017
pls delete if alredy posted.
International Conference on Cell Death in Cancer and Toxicology (CDCT-2018)
R. Birge MD
http://www.cdct2018.com/speaker.html
http://www.cdct2018.com/index.html
Jedd D. Wolchok, MD, PhD
NEW YORK, NY
NOV 19 - 21, 2017
A novel therapeutic strategy for cancer using phosphatidylserine targeting stearylamine-bearing cationic liposomes
Author links open overlay panelManjarikaDe1*SnehaGhosh1*TriparnaSen1*#Md.Shadab1IndranilBanerjee1SantanuBasu2NahidAli1
1
Infectious Diseases and Immunology Division, Indian Institute of Chemical Biology, Kolkata, West Bengal, India
2
Department of Oncology, ESI Hospital, Kolkata, West Bengal, India
Received 26 October 2017, Accepted 26 October 2017, Available online 1 November 2017.Show less
https://doi.org/10.1016/j.omtn.2017.10.019Get rights and content
Under a Creative Commons license
Abstract
There is pressing need for a ubiquitously expressed antigen or receptor on tumor surface for successful mitigation of deleterious side effects of chemotherapy. Phosphatidylserine (PS) normally constrained to the intracellular surface is exposed on the external surface of tumors and most tumorigenic cell lines. Herein, we report that a novel PS targeting liposome, phosphatidylcholine-stearylamine (PC-SA), induced apoptosis and showed potent anticancer therapy as a single agent against majority of the cancer cell lines. We experimentally proved that this was due to a strong affinity and direct interaction of these liposomes towards PS. Complexation of chemotherapeutic drugs, doxorubicin and camptothecin, in these vesicles demonstrated many fold enhancement in the efficacies of the drugs both in vitro and across three advanced tumor models without any signs of toxicity. Both free and drug loaded liposomes was maximally confined to the tumor site with low tissue concentration. These data indicate that PC-SA is a unique and promising liposome which alone and as combination therapy has anticancer potential across a wide range of cancer types
http://www.sciencedirect.com/science/article/pii/S2162253117302834
For Wolchok-Fans!
Thursday Dec 07, 2017
4:30 PM The Sidney Kimmel Comprehensive Cancer Center Director's Visiting Professor Lecture Series "Immunologic Checkpoint Blockade: Exploring Combinations and Mechanisms" featuring Jedd David Wolchok, MD, Ph.D. from Memorial Sloan Kettering Cancer Center, New York, NY
Jeff David Wolchok, MD, Ph.D.
Associate Director, Ludwig Center for Cancer Immunotherapy Memorial Sloan Kettering Cancer Center
Albert H. Owens Jr. Auditorium
Sponsored by: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
https://www.hopkinsmedicine.org/scical/